(ISRs). Among the 15,239 shots administered, 63.4% of the lenacapavir recipients reported subcutaneous nodules, while 56.4% ...

The widespread utilization of chest CT scans has increased the importance of the proper evaluation of incidentally found lung nodules. The primary goal in the evaluation of these nodules is to ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...

Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.

The thyroid gland releases T3 and T4 until the body is receiving the required amount. Most thyroid nodules do not cause symptoms and are so small that you cannot feel them. If your thyroid nodule is ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced that additional data from its pivotal Phase 3 PURPOSE 2 trial demonstrated a 96% reduction in HIV infections with Lenacapavir compared to the ...

Nodules occur because lenacapavir is injected under the skin where it forms a drug depot. Injection site reactions and nodule size decreased with subsequent injections. This side effect and trend ...

Gilead Sciences, Inc. GILD recently announced additional efficacy, safety and demographic data from its late-stage study on lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor ...

A bi-annual injectable treatment for HIV prevention (PrEP), Lenacapavir, is being celebrated as a major advancement in the field. This followed new study results that showed a 96 per cent ...

Nodules occur because lenacapavir is injected under the skin where it forms a drug depot. Injection site reactions and nodule ...

Twenty-nine people dropped out of the study because of these, 26 in the lenacapavir arm and three in the prevention pill arm (people in this study arm received placebo jabs). The most common injection ...